SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.44+1.5%Nov 18 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BigKNY3 who wrote (4041)7/8/1998 11:43:00 PM
From: Anthony Wong  Read Replies (2) of 9523
 
BigKNY3 and all, the following are excerpts from a 8:23 pm Reuters story on VVUS:
biz.yahoo.com

''Our treatment is obviously more technique-dependent than popping a pill,'' Wilson said, but added that he hoped the drug's safety record would help it regain market share.

''I take exception to the idea that renewed sexual activity leads to more deaths,'' he said. ''They don't die on Muse.''

Wilson said the safety record of Muse beat Viagra's hands down, noting only one patient has died from Muse after more than 1 million prescriptions written since its launch in January 1997. By comparison more than 30 deaths have been attributed to Viagra's more than 2 million prescriptions.

''I'm selling the wonderful safety record of Muse ... this has a marvelous safety profile,'' Wilson said.


These guys are desperate. Haven't the FDA said that they are satisfied with the safety of Viagra? And Vivus is still using this angle to sell their drug? This is equivalent to mud-slinging. I'm sure that Muse and Viagra could co-exist, and some ED sufferers not helped by Viagra could be helped by Muse, but attacking Viagra won't bring them more sales.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext